Curis vs Inhibrx Biosciences
CRIS and INBX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRIS and INBX compare
Inhibrx Biosciences is the larger company, worth 964 times as much as Curis ($1.1B against $1.1M).
Curis scores higher on the StockData Score (7 against 1 for Inhibrx Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRIS | INBX |
|---|---|---|
| Size and price | ||
| Market cap | $1.1M | $1.1B |
| Share price | $0.542 | $74.18 |
| Change, 1 year | −98.0% | −6.3% |
| Change, 5 years | −100.0% | 93.5% |
| Beta (5Y) | −0.10 | 2.16 |
| Employees | 24 | 110 |
| StockData Score | ||
| Total score | 7 (better) | 1 |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.3× | – |
| P/B | 0.2× | – |
| FCF yield | – | −12.2% |
| Fair value | $6.75 | – |
| Margin of safety | 92.0% | – |
| Growth | ||
| Revenue growth (TTM) | −62.2% | – |
| Revenue growth, 5Y average | −2.7% (better) | −36.8% |
| Profitability | ||
| Operating margin | −203% | – |
| Net margin | −490% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −5.9× |
| Current ratio | 0.49 | 7.58 (better) |
| Altman Z-score | −96.17 | −1.02 (better) |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | −2171% | – |
| Shareholder yield | −2171% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 32.1% | 97.4% |
| Held by insiders | 20.4% | 35.4% |
| Insider net buying, 12 months | $5.5K | $6.1M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 61.8% | 35.7% |
Go deeper
- CRIS stock overview
- CRIS income statement
- CRIS valuation and score
- INBX stock overview
- INBX income statement
- INBX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.